Plasma levels of D-serine in Brazilian individuals with schizophrenia

Schizophrenia Research

Volumn 142, Issue 1-3, 2012, Pages 83-87

  Calcia, Marilia A ^a   Madeira, Caroline ^a   Alheira, Flavio V ^a   Silva, Thuany C S ^a   Tannos, Filippe M ^a   Vargas Lopes, Charles ^a   Goldenstein, Nelson ^a   Brasil, Marco Antonio ^a   Ferreira, Sergio T ^a   Panizzutti, Rogerio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Aging; D serine; Negative symptoms; NMDA receptor; Schizophrenia

Indexed keywords

DEXTRO SERINE; NEUROLEPTIC AGENT; SERINE;

ADULT; AGE DISTRIBUTION; AMINO ACID BLOOD LEVEL; ARTICLE; BRAZIL; CAUSAL ATTRIBUTION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING;

ADULT; AGED; BRAZIL; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SERINE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84869880210     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.09.014     Document Type: Article

References (42)

1. Bado P., Madeira C., Vargas-Lopes C., Moulin T.C., Wasilewska-Sampaio A.P., Maretti L., de Oliveira R.V., Amaral O.B., Panizzutti R. Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology (Berl) 2011, 218:461-470.
2. Basu A.C., Tsai G.E., Ma C.L., Ehmsen J.T., Mustafa A.K., Han L., Jiang Z.I., Benneyworth M.A., Froimowitz M.P., Lange N., Snyder S.H., Bergeron R., Coyle J.T. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol. Psychiatry 2009, 14:719-727.
3. Bech P., Larsen J.K., Andersen J. Psychometric developments. Psychopharmacol. Bull. 1986, 24:118-120.
4. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90:41-51.
5. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13675-13680.
6. De Miranda J., Santoro A., Engelender S., Wolosker H. Human serine racemase: molecular cloning, genomic organization and functional analysis. Gene 2000, 256:183-188.
7. Friedman M. Chemistry, nutrition and microbiology of D-amino acids. J. Agric. Food Chem. 1999, 47:3457-3479.
8. Goltsov A.Y., Loseva J.G., Andreeva T.V., Grigorenko A.P., Abramova L.I., Kaleda V.G., Orlova V.A., Moliaka Y.K., Rogaev E.I. Polymorphism in the 5'-promoter region of serine racemase gene in schizophrenia. Mol. Psychiatry 2006, 11:325-326.
9. Habl G., Zink M., Petroianu G., Bauer M., Schneider-Axmann T., von Wilmsdorff M., Falkai P., Henn F.A., Schmitt A. Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. J. Neural Transm. 2009, 116:1657-1665.
10. Hashimoto A., Nishikawa T., Oka T., Takahashi K., Hayashi T. Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-L-cysteine and o-phthaldialdehyde. J. Chromatogr. 1992, 582:41-48.
11. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
12. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Lyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:767-769.
13. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57:577-585.
14. Hons J., Zirko R., Ulrychova M., Cermakova E., Libiger J. D-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects. Neuro Endocrinol. Lett. 2008, 29:485-492.
15. Horiike K., Tojo H., Arai R., Nozaki M., Maeda T. D-aminoacid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain Res. 1994, 652:297-303.
16. Kapoor R., Lim K.S., Cheng A., Garrick T., Kapoor V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res. 2006, 1106:205-210.
17. Labrie V., Fukumura R., Rastogi A., Fick L.J., Wang W., Boutros P.C., Kennedy J.L., Semeralul M.O., Lee F.H., Baker G.B., Belsham D.D., Barger S.W., Gondo Y., Wong A.H., Roder J.C. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum. Mol. Genet. 2009, 18:3227-3243.
18. Labrie V., Wong A.H., Roder J.C. Contributions of the D-serine pathway to schizophrenia. Neuropharmacology 2012, 62:1484-1503.
19. Luby E., Cohen B., Rosenbaum G., Gottlieb J., Kelley R. Study of a new schizophrenomimetic drug; sernyl. Am. Med. Assoc. Arch. Neurol. Psychiatry 1959, 81:363-369.
20. Madeira C., Freitas M.E., Vargas-Lopes C., Wolosker H., Panizzutti R. Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 2008, 101:76-83.
21. Matsuda S., Matsuzawa D., Nakazawa K., Sutoh C., Ohtsuka H., Ishii D., Tomizawa H., Iyo M., Shimizu E. d-serine enhances extinction of auditory cued fear conditioning via ERK1/2 phosphorylation in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:895-902.
22. Morita Y., Ujike H., Tanaka Y., Otani K., Kishimoto M., Morio A., Kotaka T., Okahisa Y., Matsushita M., Morikawa A., Hamase K., Zaitsu K., Kuroda S. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol. Psychiatry 2007, 61:1200-1203.
23. Mothet J.P., Parent A.T., Wolosker H., Brady R.O., Linden D.J., Ferris C.D., Rogawski M.A., Snyder S.H. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4926-4931.
24. Mothet J.P., Rouaud E., Sinet P.M., Potier B., Jouvenceau A., Dutar P., Videau C., Epelbaum J., Billard J.M. A critical role for the glial-derived neuromodulator d-serine in the age-related deficits of cellular mechanisms of learning and memory. Aging Cell 2006, 5:267-274.
25. Ohnuma T., Sakai Y., Maeshima H., Hatano T., Hanzawa R., Abe S., Kida S., Shibata N., Suzuki T., Arai H. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1905-1912.
26. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
27. Panatier A., Theodosis D.T., Mothet J.P., Touquet B., Pollegioni L., Poulain D.A., Oliet S.H. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 2006, 125:775-784.
28. Panizzutti R., Rausch M., Zurbrügg S., Baumann D., Beckmann N., Rudin M. The pharmacological stimulation of NMDA receptors via co-agonist site: an fMRI study in the rat brain. Neurosci. Lett. 2005, 380:111-115.
29. Potier B., Turpin F.R., Sinet P.M., Rouaud E., Mothet J.P., Videau C., Epelbaum J., Dutar P., Billard J.M. Contribution of the d-serine-dependent pathway to the cellular mechanisms underlying cognitive aging. Front. Aging Neurosci. 2010, 2:1.
30. Sacchi S., Bernasconi M., Martineau M., Mothet J.P., Ruzzene M., Pilone M.S., Pollegioni L., Molla G. pLG72 modulates intracellular d-serine levels through its interaction with d-amino acid oxidase: effect on schizophrenia susceptibility. J. Biol. Chem. 2008, 283:22244-22256.
31. Sagud M., Mihaljević-Peles A., Mück-Seler D., Pivac N., Vuksan-Cusa B., Brataljenović T., Jakovljević M. Smoking and Schizophrenia. Psychiatr. Danub. 2009, 21:371-375.
32. Sakurai S., Ishii S., Umino A., Shimazu D., Yamamoto N., Nishikawa T. Effects of psychotomimetic and antipsychotic agents on neocortical and striatal concentrations of various amino acids in the rat. J. Neurochem. 2004, 90:1378-1388.
33. Schell M.J., Molliver M.E., Snyder S.H. D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate stimulated release. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3948-3952.
34. Singh S.P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25:859-885.
35. Steffek A.E., Haroutunian V., Meador-Woodruff J.H. Serine racemase protein expression in cortex and hippocampus in schizophrenia. Neuroreport 2006, 17:1181-1185.
36. Targum S.D., Abbott J.L. Pyschosis in the elderly: a spectrum of disorders. J. Clin. Psychiatry 1999, 60:4-10.
37. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 1998, 44:1081-1089.
38. Tuominen H.J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2005, 72:225-234.
39. Verrall L., Walker M., Rawlings N., Benzel I., Kew J.N., Harrison P.J., Burnet P.W. D-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur. J. Neurosci. 2007, 26:1657-1669.
40. Wolosker H., Sheth K.N., Takahashi M., Mothet J.P., Brady R.O., Ferris C.D., Snyder S.H. Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:721-725.
41. Yamada K., Ohnishi T., Hashimoto K., Ohba H., Iwayama-Shigeno Y., Toyoshima M., Okuno A., Takao H., Toyota T., Minabe Y., Nakamura K., Shimizu E., Itokawa M., Mori N., Iyo M., Yoshikawa T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol. Psychiatry 2005, 57:1493-1503.
42. Zhang Z., Gong N., Wang W., Xu L., Xu T.L. Bell-shaped D-serine actions on hippocampal long-term depression and spatial memory retrieval. Cereb. Cortex 2008, 18:2391-2401.